TY - JOUR
T1 - Variation in Inhaled Medication Use for Infants With Congenital Heart Disease and Bronchiolitis
AU - Ahuja, Namrata
AU - Richardson, Troy
AU - Brady, Patrick
AU - Foster, Byron A.
AU - Godown, Justin
AU - Lu, Elise
AU - Madsen, Nicolas
AU - Shah, Samir S.
AU - Wagner, Tamara
AU - Wu, Susan
AU - Russell, Christopher
N1 - Publisher Copyright:
© 2023 by the American Academy of Pediatrics.
PY - 2023
Y1 - 2023
N2 - BACKGROUND AND OBJECTIVES: Current viral bronchiolitis guidelines exclude infants with congenital heart disease (CHD). Variations in the use of common therapeutics in this population and their associations with clinical outcomes are unknown. Our objective was to evaluate variations in (1) the use of b-2-agonists and hypertonic saline across hospitals among infants with CHD hospitalized with bronchiolitis, and (2) hospital-level associations between medication use and outcomes. METHODS: We performed a multicenter retrospective cohort study using administrative data from 52 hospitals in the Pediatric Health Information System.We included infants #12 months old hospitalized from January 1, 2015 to June 30, 2019 for bronchiolitis with a secondary diagnosis of CHD. Primary exposures were the hospital-level proportion of days that patients received b-2-agonists or hypertonic saline. Linear regression models assessed the association between the primary exposure and length of stay, 7-day readmission, mechanical ventilation use, and ICU utilization, adjusting for patient covariates and accounting for clustering by center. RESULTS: We identified 6846 index hospitalizations for bronchiolitis in infants with CHD. Overall, 43% received a b-2-agonist, and 23% received hypertonic saline. The proportion of days with the use of b-2-agonists (3.6% to 57.4%) and hypertonic saline (0.0% to 65.8%) varied widely across hospitals in our adjusted model. For both exposures, adjusted models revealed no association between days of use and patient outcomes. CONCLUSIONS: For children with CHD hospitalized with bronchiolitis, hospital-level use of b-2-agonists and hypertonic saline varied widely, and their use was not associated with clinical outcomes.
AB - BACKGROUND AND OBJECTIVES: Current viral bronchiolitis guidelines exclude infants with congenital heart disease (CHD). Variations in the use of common therapeutics in this population and their associations with clinical outcomes are unknown. Our objective was to evaluate variations in (1) the use of b-2-agonists and hypertonic saline across hospitals among infants with CHD hospitalized with bronchiolitis, and (2) hospital-level associations between medication use and outcomes. METHODS: We performed a multicenter retrospective cohort study using administrative data from 52 hospitals in the Pediatric Health Information System.We included infants #12 months old hospitalized from January 1, 2015 to June 30, 2019 for bronchiolitis with a secondary diagnosis of CHD. Primary exposures were the hospital-level proportion of days that patients received b-2-agonists or hypertonic saline. Linear regression models assessed the association between the primary exposure and length of stay, 7-day readmission, mechanical ventilation use, and ICU utilization, adjusting for patient covariates and accounting for clustering by center. RESULTS: We identified 6846 index hospitalizations for bronchiolitis in infants with CHD. Overall, 43% received a b-2-agonist, and 23% received hypertonic saline. The proportion of days with the use of b-2-agonists (3.6% to 57.4%) and hypertonic saline (0.0% to 65.8%) varied widely across hospitals in our adjusted model. For both exposures, adjusted models revealed no association between days of use and patient outcomes. CONCLUSIONS: For children with CHD hospitalized with bronchiolitis, hospital-level use of b-2-agonists and hypertonic saline varied widely, and their use was not associated with clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85168450143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168450143&partnerID=8YFLogxK
U2 - 10.1542/hpeds.2022-006888
DO - 10.1542/hpeds.2022-006888
M3 - Article
C2 - 37403632
AN - SCOPUS:85168450143
SN - 2154-1663
VL - 13
SP - 710
EP - 715
JO - Hospital Pediatrics
JF - Hospital Pediatrics
IS - 8
ER -